This article is more than 5 years old. Information may no longer be current.

Israel grants approval for phase 2 clinical trial of dry eye syndrome drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PETACH TIKVA, Israel — The Israeli Ministry of Health has granted approval for Can-Fite BioPharma to conduct a phase 2 trial of an investigational oral treatment for dry eye syndrome, the company announced.

The trial will include 50 patients at medical centers in Israel. Company officials also plan to report both the study protocol and results to the U.S. Food and Drug Administration, according to a press release from Can-Fite.

The drug, called CF101, is an oral tablet that targets A3 adenosine receptors on the surface of pathologic cells, according to the company. The company began developing the drug for dry eye indications after it was noted that patients experienced relief of dry eye symptoms during phase 2a trials of the drug for treatment of rheumatoid arthritis, according to the release.